来自MSN1 年
R21/Matrix-M vaccine gets WHO green light for global rollout
R21/Matrix-M™ the highly effective malaria vaccine developed by The University of Oxford and the Serum Institute of India, leveraging Novavax's adjuvant technology, has been awarded ...
Pharmabiz16 天
Novavax inks agreement to sell its Czech Republic manufacturing site to Novo Nordisk for ...
Novavax inks agreement to sell its Czech Republic manufacturing site to Novo Nordisk for $200 million: Gaithersburg, Maryland Thursday, December 5, 2024, 11:00 Hrs [IST] Novavax, ...
Daily17 天
Novavax to sell Bohumil manufacturing facility to Novo Nordisk for USD 200 million
Gaithersburg: Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, today announced ...
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Medindia12 天
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
Dec. 10, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the first participants have been ...